<- Go Home

Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.

Market Cap

$19.3M

Volume

28.5K

Cash and Equivalents

$16.0M

EBITDA

-$19.5M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

N/A

Profit Margin

N/A

52 Week High

$14.26

52 Week Low

$0.80

Dividend

N/A

Price / Book Value

1.36

Price / Earnings

-1.37

Price / Tangible Book Value

1.36

Enterprise Value

$32.3M

Enterprise Value / EBITDA

-1.76

Operating Income

-$19.7M

Return on Equity

-67.28%

Return on Assets

-21.89

Cash and Short Term Investments

$16.0M

Debt

$29.0M

Equity

$14.2M

Revenue

N/A

Unlevered FCF

-$16.0M

Sector

Biotechnology

Category

N/A

Company Stock Pitches